Amanote Research

Amanote Research

    RegisterSign In

Are Biomarkers Valid as Surrogates for Treatment Effects in Alzheimer’s Disease?

European Neurological Review - United Kingdom
doi 10.17925/enr.2009.04.01.13
Full Text
Open PDF
Abstract

Available in full text

Categories
Neurology
Date

January 1, 2009

Authors
Philip Scheltens
Publisher

Touch Medical Media, Ltd.


Related search

Biomarkers of Alzheimer’s Disease

English

Sleep Deprivation and Plasma Biomarkers for Alzheimer’s Disease

Sleep Medicine
Medicine
2019English

Plasma Biomarkers Are Associated With Agitation and Regional Brain Atrophy in Alzheimer’s Disease

Scientific Reports
Multidisciplinary
2017English

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Neurology and Therapy
Neurology
2019English

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Neurology and Therapy
Neurology
2019English

Electroencephalogram Based Biomarkers for Detection of Alzheimer’s Disease

2019English

Diagnosis of Alzheimer’s Disease Utilizing Amyloid and Tau as Fluid Biomarkers

Experimental and Molecular Medicine
BiochemistryMedicineClinical BiochemistryMolecular BiologyMolecular Medicine
2019English

PPARγ Agonists as Therapeutics for the Treatment of Alzheimer’s Disease

Neurotherapeutics
NeurologyPharmacology
2008English

Searching Biomarkers for Mental Disorders—lessons From Alzheimer’s Disease

European Archives of Psychiatry and Clinical Neuroscience
MedicinePsychiatryMental HealthBiological PsychiatryPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy